drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Engineered autologous T cells expressing a chimeric antigen receptor targeting BCMA on malignant plasma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor that recognizes BCMA on malignant plasma cells. CAR engagement activates CD3ζ signaling with costimulatory domains (e.g., 4-1BB or CD28), driving T‑cell proliferation, cytokine release, and perforin/granzyme‑mediated cytotoxic killing of BCMA‑positive myeloma cells.
drug_name
BCMA-directed CAR T cells
nct_id_drug_ref
NCT06205823